Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Copeland

Showing results (401-410 of 449) with videos related to

Pageof 45
Sort By:
Gynecologic Oncology|March 16, 2021
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundationBradley J Monk, Robert L Coleman, Thomas J Herzog, et al.
Gynecologic Oncology|March 29, 2026
Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility studyJulia Chalif, Catherine Moruzzi, Jessica Velasquez, et al.
Gynecologic Oncology|June 1, 2025
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapyQuinn Kistenfeger, Paulina J Haight, Monica Levine, et al.
Gynecologic Oncology|January 22, 2022
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation studyBrian M Slomovitz, Virginia L Filiaci, Joan L Walker, et al.
Obstetrics and Gynecology|June 8, 2022
In ReplyJohn K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
Gynecologic Oncology|September 23, 2023
The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancerPaulina J Haight, Quinn Kistenfeger, Courtney J Riedinger, et al.
Obstetrics and Gynecology|January 6, 2022
Symptoms of Women With High-Risk Early-Stage Ovarian CancerJohn K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
Gynecologic Oncology|January 23, 2024
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistanceMonica D Levine, Heather Wang, Bhargavi Sriram, et al.
Surgical Oncology|September 6, 2020
Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerationsDavid A Barrington, Ashley S Felix, Rieham Owda, et al.
Gynecologic Oncology Reports|September 2, 2025
Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinomaJulia Chalif, Molly Morton, Eric McLaughlin, et al.
Pageof 45

Showing results (401-410 of 449) with videos related to

Sort By:
Pageof 45
Gynecologic Oncology|March 16, 2021
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundationBradley J Monk, Robert L Coleman, Thomas J Herzog, et al.
Gynecologic Oncology|March 29, 2026
Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility studyJulia Chalif, Catherine Moruzzi, Jessica Velasquez, et al.
Gynecologic Oncology|June 1, 2025
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapyQuinn Kistenfeger, Paulina J Haight, Monica Levine, et al.
Gynecologic Oncology|January 22, 2022
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation studyBrian M Slomovitz, Virginia L Filiaci, Joan L Walker, et al.
Obstetrics and Gynecology|June 8, 2022
In ReplyJohn K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
Gynecologic Oncology|September 23, 2023
The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancerPaulina J Haight, Quinn Kistenfeger, Courtney J Riedinger, et al.
Obstetrics and Gynecology|January 6, 2022
Symptoms of Women With High-Risk Early-Stage Ovarian CancerJohn K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
Gynecologic Oncology|January 23, 2024
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistanceMonica D Levine, Heather Wang, Bhargavi Sriram, et al.
Surgical Oncology|September 6, 2020
Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerationsDavid A Barrington, Ashley S Felix, Rieham Owda, et al.
Gynecologic Oncology Reports|September 2, 2025
Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinomaJulia Chalif, Molly Morton, Eric McLaughlin, et al.
Pageof 45